RSV vaccines Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Abrysvo RSV vaccine safety data – pregnant participants Arexvy RSV vaccine safety data – older adults Shingrix AusVaxSafety is conducting active vaccine safety surveillance of recently introduced respiratory syncytial virus (RSV) vaccines in Australia to ensure their ongoing safety.The RSV vaccines registered for use in Australia are:Arexvy – registered for use in adults aged 60 years and overAbrysvo – registered for use in pregnant people and adults aged 60 years and over.Safety data are gathered via the AusVaxSafety surveillance program and are based on vaccine safety surveys sent in the days following RSV vaccination. Data on this page are updated monthly.Latest RSV vaccine safety dataClick on the tiles below to view AusVaxSafety RSV vaccine safety data for specific age and population groups.Note: Vaccine safety data for additional population groups will be added once enough data are collected to enable meaningful analysis. Abrysvo RSV vaccine safety data – pregnant participants View the latest safety data here Arexvy RSV vaccine safety data – older adults View the latest safety data here Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Abrysvo RSV vaccine safety data – pregnant participants Arexvy RSV vaccine safety data – older adults Shingrix News & events All news & events 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations 18 May 2025 | News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination 31 March 2025 | News AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines